Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors
December 3rd 2000Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly